C2N Diagnostics and Eisai Inc. announced the Companies have entered into a memorandum of understanding that will seek to build awareness about how blood-based assays for cognitive impairment, including Alzheimer’s disease (AD), may help patients receive a timely diagnosis and appropriate treatment, especially in traditionally underserved communities. C2N and Eisai will work to build awareness and develop real-world evidence to support the use of blood-based assays in people living with cognitive impairment who are not currently participating in a clinical trial. The development and adoption of blood-based assays in everyday clinical practice is an important step in improving care for people in remote and underserved communities where access to the traditional diagnostic tools of positron emission tomography (PET) and lumbar punctures are not a viable option.
Also Read: FDA Approves Abbott New Spinal Cord Stimulation Device
The number of people with dementia is growing substantially; more than 55 million people worldwide are living with dementia, and this number is expected to increase to 78 million by 2030.1 Accurate diagnosis remains a barrier to early and proper care management; research reviews estimate that between 40 and 60 percent of adults with probable dementia are undiagnosed.2 Importantly, blood-based assays may be able to help identify which patients may benefit from therapy, and therefore may help streamline care and reduce healthcare spending. Early detection, diagnosis and treatment of dementia protects individuals against risks from delayed or missed diagnosis and allows individuals, their families and their caregivers to plan for the future as the condition progresses.2
“We must do more to provide a specific and timely diagnosis of dementia. Patients and families want to know, and that’s why this collaboration is so vital. We’re honored to be working with Eisai, which is recognized as a leader in innovation, evidence-based solutions to patient care, and we join them in a shared commitment to improving global health for individuals dealing with memory impairment and Alzheimer’s disease,” said Dr. Joel Braunstein, CEO, C₂N Diagnostics.
“As the science of Alzheimer’s disease rapidly progresses, it is critical that healthcare providers have simple tools to diagnose people living with early Alzheimer’s disease in a variety of real-world settings, not just clinical trials,” said Ivan Cheung, Chairman and CEO of Eisai Inc., Global Alzheimer’s Disease Officer, and Senior Corporate Officer, Eisai Co., Ltd. “For four decades Eisai has been at the forefront of Alzheimer’s disease research, and we are proud to combine efforts with C2N Diagnostics, as we are impressed with their approach and achievements in the field. Eisai and C2N will support the development of new standards in clinical care that may enable timely and accurate diagnoses for people living with cognitive impairment, especially those in traditionally underserved communities.”